

Northwestern Medicine Central DuPage Hospital

Antimicrobial Criteria

Updated 11/16/16

These criteria are based on national and local susceptibility data as well as Infectious Disease Society of America (IDSA) guideline recommendations.

Certain newer antibiotics require an Infectious Diseases consult and there is an ordering question in EPIC which asks if ID has been consulted.

Certain antibiotics such as daptomycin and linezolid are not mandatory ID consults, but ID consult is highly recommended to ensure appropriate use

Certain antimicrobials are restricted to Infectious Disease Consultation due to their toxicity, cost or specific indications.

Pharmacy Process

- If a restricted antibiotic is ordered (where ID consult is recommended but not required), the pharmacist will use the criteria listed below to ensure the use is appropriate. If criteria is met, the order will be processed.
- If the restricted antibiotic (where ID consult is recommended but not required) does not meet criteria for use, Pharmacy or ASP will contact provider for clarification and suggest alternative options. ID consult is recommended in such cases.
- If an antibiotic restricted to Infectious Diseases is ordered M-F 8am-5pm, pharmacy will not process the order until ID consultation has been obtained.
- If an antibiotic restricted to Infectious Diseases is ordered after 5pm M-F or weekends/holidays, pharmacy will approve 1-2 doses until ID consultation has been obtained next day.

ID Pharmacist

Radhika S. Polisetty Pharm.D., BCPS, AQ-ID
Phone number 630-315-8699

Rachael Craft PharmD

PGY2 ID Resident
Phone number 630-315-6968

ID Physicians

Luis Manrique MD
Jennifer De La Cruz MD
Northwestern Medicine Department of Infectious Disease

Amphotericin B- ID Consult recommended

Use is restricted to irrigation, inhalation per the lung transplant protocol, or special intraocular uses. Conventional amphotericin B is not to be used for intravenous treatment. For intravenous treatment with an amphotericin B product, liposomal amphotericin B (AmBisome®) should be used.

Aztreonam

Use is restricted to penicillin-allergic and cephalosporin-allergic patients who require gram-negative coverage.

Ceftaroline fosamil - ID Consult required

- MRSA endocarditis in patients with:
 - Persistently positive blood cultures while on IV vancomycin therapy (of note, mean duration is 7 days for vancomycin-treated MRSA bacteremia in endovascular [i.e., endocarditis] infection)
OR
 - Inability to tolerate vancomycin therapy due to allergy (excluding red man's syndrome)
OR
 - Inability to tolerate vancomycin due to a current episode of moderate to severe acute kidney injury (AKI).
- Polymicrobial skin and soft tissue infections
- Culture-documented MRSA pneumonia.
- Empiric use for suspected MRSA hospital acquired, ventilator associated, or health care associated pneumonia in a critically ill patient. Subsequent documentation of MRSA from culture is required for use beyond 72 hours.
- Empiric use for suspected MRSA pneumonia in hemodynamically stable (floor) patients with:
 - Cystic fibrosis patients
OR
 - Inability to tolerate vancomycin due to allergy (excluding red man's syndrome)
OR
 - Inability to tolerate IV vancomycin therapy due to a current episode of moderate to severe AKI.

Ceftazidime\Avibactam- ID Consult required

Ordering of ceftazidime\avibactam is restricted to patients who are being followed by the ID consultation service and ID consultation is recommending use of this agent.

Do not use this drug when a highly-resistant Gram-negative organism is isolated in a hemodynamically stable patient in whom the only source is a symptomatic, non-complicated UTI.

Use is restricted to patients with:

- Definitive extended spectrum beta-lactamase (ESBL) resistance to all available antibiotics AND failure of current first line therapies (i.e., carbapenem) AND known susceptibility to ceftazidime\avibactam
- Definitive carbapenem-resistant enterobacteriaceae (CRE) infection AND failure of current first line therapies (i.e., multiple drug therapy with carbapenem +/- aminoglycoside +/- polymyxin b +/- other active agents) AND known susceptibility to ceftazidime\avibactam

Ceftolozane\Tazobactam- ID Consult required

Ordering of ceftolozane/tazobactam is restricted to patients who are being followed by the ID consultation service and ID consultation is recommending use of this agent.

Use is restricted to non-cystic fibrosis patients with:

- Definitive multidrug resistant *Pseudomonas aeruginosa* with known resistance to all available antibiotics AND known susceptibility to ceftolozane/tazobactam
- Definitive extended spectrum beta-lactamase (ESBL) infection AND known susceptibility to ceftolozane/tazobactam

Each order of ceftolozane/tazobactam must be reviewed by the antimicrobial stewardship (ASP) pharmacist

Dalfopristin/Quinupristin- ID Consult required

Use is restricted to:

- Patients with vancomycin resistant *Enterococcus* (VRE) *faecium* infections that are unable to receive linezolid or daptomycin (due to resistance and/or intolerance).
- Patients with methicillin-resistant *Staphylococcus aureus* (MRSA) infections who are unable to receive vancomycin, linezolid, and daptomycin (due to resistance, allergy, and/or severe intolerance).

Dalbavancin- ID Consult Required, Outpatient Use only

Acute complicated skin and soft tissue infections caused by gram positive agents such as MRSA
Approved for use in the outpatient infusion center only

Daptomycin- ID Consult recommended

Daptomycin should not be used for pneumonia as this antibiotic is inactivated by surfactant.

Use is restricted to:

- MRSA endocarditis in patients with:
 - Persistently positive blood cultures while on IV vancomycin therapy (of note, mean duration is 7 days for vancomycin-treated MRSA bacteremia in endovascular [i.e., endocarditis] infection)
OR
 - Inability to tolerate vancomycin therapy due to allergy (excluding red man's syndrome)
OR
 - Inability to tolerate vancomycin due to a current episode of moderate to severe acute kidney injury (AKI).
- In many cases, vancomycin dosing may be adequately managed by pharmacy – please consult your pharmacist for recommendations.
- Systemic MRSA infections (excluding pneumonia) in patients with:
 - Inability to tolerate vancomycin therapy due to allergy (excluding red man's syndrome)
OR
 - Inability to tolerate vancomycin due to a current episode of moderate to severe acute kidney injury (AKI).
- In many cases, vancomycin dosing may be adequately managed by pharmacy –please consult your pharmacist for recommendations.
- Methicillin-susceptible *Staphylococcus aureus* (MSSA) bacteremia in patients with either of the following:
 - Allergy to beta-lactams and vancomycin therapy (excluding red man's syndrome)
OR
 - Allergic to beta-lactams and inability to tolerate vancomycin due to a current episode of moderate to severe AKI.
- In many cases, vancomycin dosing may be adequately managed by pharmacy – please consult your pharmacist for recommendations.

- VRE infections in patients allergic or resistant to penicillins and/or in patients having hematological abnormalities precluding linezolid use. Of note, Infectious Disease Consultation is strongly recommended for severe VRE infections such as endocarditis for dosing and for combination therapy recommendations.
- Gram positive cocci (GPC) bacteremia in stem-cell transplant patient with VRE colonization until culture results are available.

Dual Antifungal Therapy

Use is restricted to:

- Approval from Infectious Diseases Consultation Service with complete evaluation of the patient and clinical setting.
- Probable or proven invasive aspergillosis in a hematologic malignancy or stem cell transplant patient (echinocandin plus azole antifungal only).

Imipenem-Non-formulary carbapenem. ID consult recommended

Use is restricted to patients with documented infections resistant to all other potentially effective antimicrobials on formulary, including meropenem.

Isavuconazole- Non-Formulary at CDH/Delnor

Use is restricted to:

- Probable or proven invasive Mucormycosis in patients who are failing liposomal amphotericin B treatment or who are experiencing complications that preclude its use.

AND

- Approval from Infectious Diseases Consultation Service with complete evaluation of the patient and clinical setting.

Linezolid- ID consult recommended

Use is restricted to:

- MRSA infections in patients with:
 - Inability to tolerate vancomycin due to allergy (excluding red man's syndrome)
 - OR
 - Inability to tolerate vancomycin due to a current episode of moderate to severe AKI.
 - In many cases, vancomycin dosing may be adequately managed by pharmacy – please consult your pharmacist for recommendations.
- Culture-documented MRSA pneumonia.
- Empiric use for suspected MRSA hospital acquired, ventilator associated, or health care associated pneumonia in a critically ill patient. Subsequent documentation of MRSA from culture is required for linezolid continuation beyond 72 hours.
- Empiric use for suspected MRSA pneumonia in hemodynamically stable (floor) patients with:
 - Cystic fibrosis patients
 - OR
 - Inability to tolerate vancomycin due to allergy (excluding red man's syndrome)
 - OR
 - Inability to tolerate IV vancomycin therapy due to a current episode of moderate to severe AKI.

- In many cases, vancomycin dosing may be adequately managed by pharmacy – please consult your pharmacist for recommendations.
- GPC bacteremia in a febrile neutropenic patient with VRE colonization until culture results available.
- Documented or strongly suspected systemic VRE infections that are:
 - Also ampicillin-resistant
OR
 - Ampicillin-susceptible in patients allergic to penicillins.
 - Documented VRE in the urine of:
 - A pregnant patient
OR
 - An immunocompromised (neutropenic or transplant) patient
OR
 - An immunocompetent patient with systemic symptoms such as dysuria, fever, elevated WBC, and rigors.
 - Asymptomatic bacteriuria in an immunocompetent patient should not be treated.

Meropenem- Formulary Carbapenem- ID consult recommended

Use is restricted to:

- Patients with a positive blood, deep respiratory (BAL), or other clinically significant sterile site culture with an ESBL producing organism (floor or ICU patient).
- Empiric use in critically ill ICU patients with prior documentation of ESBL organism.
- Critically ill ICU patients failing > 72 hours of cefepime or piperacillin/tazobactam therapy.

Micafungin- Formulary Echinocandin, ID consult recommended

Use is restricted to patients with:

- Documented or suspected aspergillosis who are refractory or intolerant to amphotericin products and voriconazole.
- Empiric antifungal therapy when necessary in neutropenic patients who remain febrile despite broad spectrum antibiotic therapy for greater than 3 days.
- Empiric use in patients with yeast bloodstream infections. If *Candida albicans* is identified, micafungin should be deescalated to fluconazole.
- Suspected candidiasis in patients with recent azole exposure, moderately severe to severe illness, or high risk of *C. glabrata* or *C. krusei*.
- Candida isolates that have documented clinical or microbiologic resistance to fluconazole.

Micafungin should not be used for fungal urinary tract infections as this drug is not excreted in the urine.

Nafcillin -ID consult recommended

Use is restricted to:

- Infectious Diseases consultation
- MSSA meningitis
- MSSA CNS parenchymal abscess

Tigecycline- ID consult required

Use is restricted to Infectious Diseases consultation only.

Posaconazole- Non-Formulary, ID consult required

Use is restricted to:

- Infectious Diseases consultation
- Continuation of outpatient posaconazole therapy
- Lung transplant patients

Voriconazole- ID consult recommended

Use is restricted to:

- Fungal prophylaxis in high-risk bone marrow transplant patients
- Patients with documented or strongly suspected invasive aspergillosis. The following are criteria that help identify patients as being strongly suspected of having invasive aspergillosis:
 - Biopsy specimen consistent with aspergillus.
 - Halo or air-crescent sign on lung CT.
 - Radiologic evidence of new pulmonary lesions not attributable to other factors with respiratory sample containing hyphae consistent with aspergillus.

NON-FORMULARY ANTIMICROBIAL AGENTS

Non-formulary antimicrobial agents must go through the non-formulary request process regardless of who is requesting use of the agent.

Please page the ID pharmacist x58699 or Pharmacy Clinical coordinator at x32400 to initiate the non-formulary process for an antimicrobial agent.

ANTI-INFECTIVE SHORTAGES

When an anti-infective agent is unavailable or in severely limited supply, ASP may alter the NMH CDH formulary restrictions temporarily and notify health care workers of alternative agents for specific indications.